Global Obsessive-Compulsive Disorder Drugs Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Obsessive-Compulsive Disorder Drugs Market was valued at $820 mn. in 2025. During the forecast period 2025-2030, it is expected to grow at 9.2% CAGR, to an estimated market size of $1.3 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global Obsessive-Compulsive Disorder (OCD) drugs market encompasses the sale of pharmaceutical therapies specifically indicated or used off-label for the management of OCD symptoms. This includes Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), and adjunctive treatments such as antipsychotics and emerging glutamate-modulating agents. The scope excludes standalone psychotherapy and non-pharmacological medical devices unless they are part of an integrated drug-delivery system.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Obsessive-Compulsive Disorder Drugs Market in the period 2025-30:
- The development of novel drug classes such as glutamate-modulating agents like troriluzole is expected to address the high unmet need in treatment-resistant OCD patients.
- Rising mental health awareness and global destigmatization efforts are significantly increasing patient screening and clinical diagnosis rates.
- There is an increasing shift toward personalized medicine where genomic research helps clinicians select the most effective pharmacological interventions based on individual neurobiology.
- The integration of digital therapeutics and AI-driven symptom tracking is enhancing medication adherence and providing real-time data for dosage optimization.
- Growing clinical acceptance of off-label combination therapies, particularly adding atypical antipsychotics to standard SSRI regimens, is driving market volume.
- The expansion of telepsychiatry and online pharmacy platforms is improving access to specialized OCD medications in underserved and rural populations.
- Pharmaceutical companies are increasingly focusing on extended-release formulations to improve pharmacokinetic profiles and reduce the side-effect burden on patients.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- SSRIs
- TCAs
- Other Drugs (Antipsychotics, NMDA blockers, etc.)